APA (7th ed.) Citation

Wu, R., Kong, P., Xia, L., Huang, Y., Li, Z., Tang, Y., . . . Zhu, X. (2019). Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. Clinical cancer research, 25(14), 4530-4541. https://doi.org/10.1158/1078-0432.CCR-18-2840

Chicago Style (17th ed.) Citation

Wu, Rui-Yan, et al. "Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma." Clinical Cancer Research 25, no. 14 (2019): 4530-4541. https://doi.org/10.1158/1078-0432.CCR-18-2840.

MLA (9th ed.) Citation

Wu, Rui-Yan, et al. "Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma." Clinical Cancer Research, vol. 25, no. 14, 2019, pp. 4530-4541, https://doi.org/10.1158/1078-0432.CCR-18-2840.